Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHIFT + nanoICG
- Development stage
- Unknown
- Lead developer
- Xiamen University
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intra-arterial
01
Overview
SHIFT + nanoICG is a nanomedicine formulation developed for the integrated diagnosis and treatment of hepatocellular carcinoma (HCC). The formulation utilizes Super-stable Homogeneous Intermixed Formulation Technology (SHIFT) to disperse carrier-free indocyanine green nanoparticles (nanoICG) into lipiodol, an iodized oil commonly used in transcatheter arterial embolization (TAE). Administered via the hepatic artery, the formulation exploits the enhanced permeability and retention (EPR) effect and the tumor-seeking properties of lipiodol to achieve specific deposition within liver tumors. This enables long-lasting near-infrared fluorescence imaging for surgical navigation, allowing for the detection of microsatellite lesions as small as 0.4 cm that are often invisible on preoperative imaging. The formulation also provides therapeutic benefit through embolization and has demonstrated improved stability and anti-photobleaching properties compared to molecular ICG.
- Other names
- nanoICG-lipiodol formulationindocyanine green nanoparticles in lipiodolnanoICGSHIFT-nanoICG
Beyond the preview
Go deeper on SHIFT + nanoICG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHIFT + nanoICG.